Is Egrifta (Tesamorelin) Legal in New York?
HealthRX.com
Egrifta is FDA-approved, but New York rules are separate
See the public record for Tesamorelin
At a glance
- FDA status / Approved prescription drug, application BLA 022505, first approved November 10, 2010 [1]
- Current labels / Egrifta SV 2 mg vial and Egrifta WR 11.6 mg vial, both dated July 29, 2026 [2][3]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]
- Not approved for / Weight loss; the label calls the effect weight-neutral [2]
- Compounding / Not on FDA's significant-safety-risk list or its state-licensed pharmacy or outsourcing facility category lists [4][5][6]
- HHS peptide policy / Not one of the six peptides in the October 2026 draft enforcement-discretion policy [7][8]
- Sport / WADA names it in S2.2.4 and prohibits it at all times [9][10]
What does FDA approval mean for New York?
Egrifta was first approved on November 10, 2010, under BLA 022505 [1]. Drugs@FDA lists the 1 mg and 2 mg vials as prescription products [1]. The current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026 [2][3].
FDA approval makes Egrifta a federally approved prescription drug. State-level requirements in New York are a separate question from FDA approval.
Questions worth asking
What is it approved to treat?
The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]. The label adds limits: long-term cardiovascular safety has not been established, the risk and benefit of continuing should be considered in patients who have not had a reduction in visceral adipose tissue, and it is not indicated for weight loss because its effect on weight is neutral [2]. The label also says there are no data that it improves adherence to antiretroviral therapy [2].
Use in people without HIV lipodystrophy is outside the label, including use for general fat loss, anti-aging or muscle building [2].
Can tesamorelin be compounded?
Tesamorelin is not on FDA's list of bulk substances that may present significant safety risks; that list is dated April 22, 2026 [4]. It also appears in no category of FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, or of FDA's list for outsourcing facilities, updated March 21, 2025 [5][6]. So FDA has made no category-based statement about compounding it [4][5][6].
Tesamorelin is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [7][8]. It is already a component of an FDA-approved drug, Egrifta [1][2]. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are marketed [8].
Is tesamorelin legal in sport?
WADA's Prohibited List names tesamorelin in S2.2.4, under growth hormone releasing factors (GHRH and its analogues) [9]. It is prohibited at all times, in and out of competition [9]. It is on the 2026 List in force since January 1, 2026, and remains on the 2027 List [9][10].
Frequently asked questions
Is Egrifta (tesamorelin) legal in New York?
Is compounded tesamorelin legal?
Is tesamorelin banned in sports?
What is the approved dose?
References
Show all 10 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- World Anti-Doping Agency.
- World Anti-Doping Agency.